Search - tctmd.com

Displaying 81 - 100 of 248

Sort: Relevancy | Date

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

News Daily News

Short DAPT Reduces Bleeding With No Increase in MACE: Meta-analysis

Yael L. Maxwell

June 30, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

News Daily News

Stent Thrombosis May Be Presenting Feature of COVID-19

Yael L. Maxwell

June 08, 2020

News Daily News

Injectable P2Y12 Inhibitor Selatogrel Shows Promise in Acute MI

Yael L. Maxwell

June 03, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Daily News

Better Adherence to Guideline Advice Pays Off After Acute MI

Yael L. Maxwell

March 11, 2020

News Daily News

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

Yael L. Maxwell

March 10, 2020

News Daily News

New ABCD-GENE Score Taps Clinical, Genetic Factors to ID Clopidogrel Nonresponders

Yael L. Maxwell

March 06, 2020

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

Shelley Wood

March 04, 2020

News Daily News

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Todd Neale

January 15, 2020

News Daily News

CV Risk Factors Largely Explain Sex Gap in NSTE ACS Outcomes: TIMI Trials

Caitlin E. Cox

December 11, 2019

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

News Daily News

Women Bleed More Than Men After PCI, GLOBAL LEADERS Affirms

Todd Neale

November 07, 2019

News Daily News

Morphine Not Linked to Increased Short-term Mortality in STEMI: Meta-analysis

L.A. McKeown

November 01, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

Advertisement

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Short DAPT Reduces Bleeding With No Increase in MACE: Meta-analysis

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Stent Thrombosis May Be Presenting Feature of COVID-19

Injectable P2Y12 Inhibitor Selatogrel Shows Promise in Acute MI

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Better Adherence to Guideline Advice Pays Off After Acute MI

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

New ABCD-GENE Score Taps Clinical, Genetic Factors to ID Clopidogrel Nonresponders

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

CV Risk Factors Largely Explain Sex Gap in NSTE ACS Outcomes: TIMI Trials

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Women Bleed More Than Men After PCI, GLOBAL LEADERS Affirms

Morphine Not Linked to Increased Short-term Mortality in STEMI: Meta-analysis

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content